This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
1.Patients fully understand and sign ICF, voluntarily participate in the study, and able to follow and complete all study procedures.
2.Aged 18-80 years (including upper and lower limits), male or female.
Surgical excision is confirmed by histology or cytology can't or metastatic patients with advanced solid tumor;
Patients with relapsed or refractory hematologic malignancies
1. The adverse reactions of previous antineoplastic therapy have not recovered to CTCAE 5.0 grade ≤1 (except for toxicities without safety risks judged by investigators, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy);
2. Clinically symptomatic parenchymal or leptomeningeal metastases that were judged by the investigator to be ineligible for enrollment and, for AML patients, known central nervous system (CNS) involvement
Nitrosourea or mitomycin C within 6 weeks before first use of study drug;
Oral fluorouracils and small-molecule targeted agents are administered 2 weeks before first use of the study drug or within the five half-lives of the drug, whichever is longer;